v3.26.3
Segment, Geographic and Other Revenue Information (Tables)
 9 Months Ended
Sep. 27, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
The following provides selected information by reportable segment:
Three Months Ended
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
(MILLIONS)Sept. 27, 2026Sept. 28, 2025Sept. 27, 2026Sept. 28, 2025Sept. 27, 2026Sept. 28, 2025
Reportable Segment:
Biopharma(c)
$16,283 $16,310 $8,241 $8,469 $326 $358 
Other business activities(d)
300 344 (2,436)(3,084)109 78 
Reconciling Items:
Amortization of intangible assets(1,128)(1,223)1,128 1,223 
Acquisition-related items(364)(194)(1)(1)
Certain significant items(e)
(928)(634)14 4 
$16,583 $16,654 $3,385 $3,334 $1,577 $1,662 
Nine Months Ended
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
(MILLIONS)Sept. 27, 2026Sept. 28, 2025Sept. 27, 2026Sept. 28, 2025Sept. 27, 2026Sept. 28, 2025
Reportable Segment:
Biopharma(c)
$45,105 $44,056 $21,967 $22,429 $998 $1,029 
Other business activities(d)
962 966 (5,811)(6,230)292 225 
Reconciling Items:
Amortization of intangible assets(3,497)(3,644)3,497 3,644 
Acquisition-related items(1,537)(814)(3)(4)
Certain significant items(e)
(5,219)(2,578)28 11 
$46,067 $45,022 $5,902 $9,162 $4,812 $4,905 
(a)Income from continuing operations before provision/(benefit) for taxes on income.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.
(c)Biopharma’s earnings include dividend income from our previous investment in ViiV of $58 million in the third quarter of 2026 and $72 million in the third quarter of 2025, and $239 million in the first nine months of 2026 and $184 million in the first nine months of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the third quarter and the first nine months of 2025 also reflected credits to Cost of Sales representing favorable revisions of our estimate of accrued royalties.
(d)Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above. Earnings in the third quarter and the first nine months of 2026 reflect a charge of $650 million recorded in Acquired in-process research and development expenses related to an in-licensing and collaboration agreement with Innovent (see Note 2E). Earnings in the third quarter and the first nine months of 2025 reflected a charge of $1.35 billion recorded in Acquired in-process research and development expenses related to an in-licensing agreement with 3SBio.
(e)Earnings in the third quarter and the first nine months of 2026 include, among other things, restructuring charges/(credits), inventory write-offs, implementation costs and additional depreciation—asset restructuring of $893 million and $1.6 billion for the third quarter and the first nine months of 2026, respectively (primarily recorded in Restructuring charges and certain acquisition-related costs). Earnings in the first nine months of 2026 also include, among other things, (i) certain asset impairments of $4.3 billion and (ii) charges for certain legal matters of $1.0 billion, partially offset by (iii) a net gain of $1.870 billion from the sale of our previous investment in ViiV (all recorded in Other (income)/deductions––net). Earnings in the first nine months of 2025 included, among other items, (i) restructuring charges/(credits), inventory write-offs, implementation costs and additional depreciation—asset restructuring of $1.0 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (ii) charges for certain legal matters of $755 million and (iii) certain asset impairments of $577 million (items (ii) and (iii) recorded in Other (income)/deductions––net). See Notes 3 and 4.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Three Months EndedNine Months Ended
(MILLIONS)September 27,
2026		September 28,
2025		September 27,
2026		September 28,
2025
Biopharma reportable segment:
Biopharma total revenues$16,283 $16,310 $45,105 $44,056 
Less:
Cost of sales3,456 3,526 9,678 8,915 
Selling, informational and administrative expenses2,300 2,210 6,775 6,739 
Research and development expenses2,580 2,185 7,094 6,235 
Acquired in-process research and development expenses19 40 172 51 
Other (income)/deductions––net(314)(120)(581)(313)
Biopharma earnings$8,241 $8,469 $21,967 $22,429 
The following provides additional revenue information for several of our major products:
(MILLIONS)Three Months EndedNine Months Ended
PRODUCTPRIMARY INDICATION OR CLASSSept. 27, 2026Sept. 28, 2025Sept. 27, 2026Sept. 28, 2025
TOTAL REVENUES$16,583 $16,654 $46,067 $45,022 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a)
$16,283 $16,310 $45,105 $44,056 
Primary Care$6,971 $7,642 $18,017 $18,869 
Eliquis(b)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism2,523 2,015 7,114 5,941 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
1,564 1,742 4,591 4,786 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine547 412 1,321 1,019 
ComirnatyActive immunization to prevent COVID-19808 1,151 1,301 2,097 
Abrysvo
Active immunization to prevent RSV infection
303 279 691 553 
Paxlovid
COVID-19 in certain high-risk patients449 1,225 656 2,144 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease104 100 317 272 
All other Primary CareVarious674 718 2,027 2,058 
Oncology$4,327 $3,938 $12,318 $11,467 
IbranceHR-positive/HER2-negative metastatic breast cancer and first-line maintenance treatment for adults with HR+, HER2+ locally advanced or metastatic breast cancer1,082 1,057 3,148 3,083 
Padcev
Locally advanced or metastatic urothelial cancer and MIBC720 464 1,979 1,432 
Xtandi(c)
mCRPC, nmCRPC, mCSPC, nmCSPC541 578 1,519 1,602 
LorbrenaALK-positive metastatic NSCLC387 268 1,046 741 
InlytaAdvanced renal cell carcinoma232 226 665 688 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(d) (after prior therapy) or cetuximab and fluorouracil-based chemotherapy
244 202 642 519 
Adcetris(e)
Certain lymphomas including classical Hodgkin lymphoma, T-cell lymphoma and relapsed/refractory diffuse large B-cell lymphoma
231 215 617 687 
Orgovyx(f)
Advanced prostate cancer
153 112 408 285 
TukysaUnresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer142 110 402 344 
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia71 150 313 450 
Elrexfio
Relapsed or refractory multiple myeloma
83 85 252 230 
Talzenna
Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC
59 47 166 133 
Tivdak
Recurrent or mCC with disease progression on or after chemotherapy
39 37 106 115 
All other Oncology
Various341 386 1,054 1,157 
Specialty Care$3,349 $3,130 $9,641 $8,834 
Vyndaqel familyATTR-CM and polyneuropathy1,773 1,591 5,136 4,692 
XeljanzRA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis213 313 643 763 
Zavicefta (Outside the U.S. and Canada)Bacterial infections179 158 528 457 
Enbrel (Outside the U.S. and Canada)RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis151 154 431 448 
Octagam
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
134 113 394 298 
(MILLIONS)Three Months EndedNine Months Ended
PRODUCTPRIMARY INDICATION OR CLASSSept. 27, 2026Sept. 28, 2025Sept. 27, 2026Sept. 28, 2025
BeneFIXHemophilia B102 94 297 285 
CresembaInvasive aspergillosis and mucormycosis100 83 294 267 
GenotropinReplacement of human growth hormone94 128 281 329 
CibinqoAtopic dermatitis101 79 272 206 
All other Specialty CareVarious503 417 1,364 1,091 
Hospital and Biosimilars(a)
$1,635 $1,600 $5,129 $4,886 
Oncology biosimilars(g)
Various
378 315 1,145 932 
InflectraCrohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis186 173 539 465 
Sulperazon (Outside the U.S. and Canada)
Bacterial infections96 154 411 484 
ZithromaxBacterial infections47 73 200 286 
All other Hospital and Biosimilars
Various
928 885 2,833 2,719 
PFIZER CENTREONE(h)
$300 $344 $962 $966 
BIOPHARMA(a)
$16,283 $16,310 $45,105 $44,056 
PFIZER U.S. COMMERCIAL DIVISION
9,677 9,854 25,319 25,437 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
5,433 5,381 16,211 15,408 
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(i)
1,172 1,075 3,576 3,211 
Total Alliance revenues included above$2,851 $2,298 $7,888 $6,684 
Total Royalty revenues included above
$477 $436 $1,347 $1,170 
(a)In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation.
(b)Reflects alliance revenues and product revenues.
(c)Primarily reflects alliance revenues and royalty revenues.
(d)Erbitux® is a registered trademark of ImClone LLC.
(e)Reflects product revenues and royalty revenues.
(f)Reflects alliance revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
(h)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in all periods presented. We reclassified prior period amounts to conform to the current period presentation.
(i)See Note 13A above.
Schedule of Revenues by Geographic Region
The following summarizes revenues by geographic area:
Three Months EndedNine Months Ended
(MILLIONS)September 27,
2026		September 28,
2025		September 27,
2026		September 28,
2025
United States$10,602 $10,691 $28,191 $27,959 
International:
Developed Markets
3,643 3,696 10,813 10,267 
Emerging Markets2,337 2,267 7,064 6,796 
Total revenues
$16,583 $16,654 $46,067 $45,022